Inovio is a step behind Moderna on the coronavirus vaccine timeline -- but study results will determine the true winner.
News & Analysis: Inovio Pharmaceuticals
The company is racing through the early stage of the development of its potential vaccine for COVID-19.
INO earnings call for the period ending March 31, 2020.
Size may matter in the long run.
Can a company that failed multiple times to deliver vaccines for previous epidemics finally succeed?
Inovio's become one of the hottest coronavirus-related stocks on the market. But does that make the stock a buy?
Inovio shares climbed as the company’s coronavirus vaccine entered clinical trials.
The answer might surprise you.
After shareholder pushback against its initial vaccine candidate announcement in February, Inovio badly needs its fraught clinical trial to succeed.
The biotech is moving quickly, but has a lot of potential competition.